Ally Bridge Group

Kandu Health is a technology-driven healthcare company focused on enhancing the quality of life for stroke survivors and their families. The company specializes in stroke recovery training, stroke detection research, and educational services. Kandu Health provides remote clinical support through its application, which delivers personalized information, resources, and guidance tailored to each participant. This approach empowers stroke survivors to take charge of their recovery and assists them in adapting to life after a stroke.

The Gene Expression Modulation System (GEMS) technology from Epic-Bio combines a DNA-binding protein, a tailored guide RNA, and any of a wide range of modulator proteins to generate a powerful new type of genetic medicine. GEMS medicines have the ability to precisely modify gene expression both in and out of the body. They are mutation-independent, which means that a single GEMS design can address the majority or all genetic subtypes of a disease.

Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Tectonic Therapeutic is a biotechnology company dedicated to the discovery and development of innovative drugs that target G protein-coupled receptors (GPCRs). With a focus on therapeutic proteins and antibodies, Tectonic aims to address the complexities of GPCR-targeted drug discovery through its proprietary technology platform, GEODe. The company is committed to unlocking the therapeutic potential of challenging receptors, striving to create biologic medicines that can effectively modify disease progression. Founded by experts in biochemistry and molecular pharmacology, Tectonic combines a strong scientific foundation with a history of entrepreneurial success to advance its mission in the biopharmaceutical landscape.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). It was founded in 2004 and headquartered in Toronto, Canada.

Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

InSightec Ltd. specializes in developing and distributing the Exablate platform, which employs MR-guided focused ultrasound technology for non-invasive medical treatments in oncology and gynecology. The company offers solutions such as Exablate Neuro, designed for personalized thalamotomy to address movement disorders and pain without invasive surgery, and a thermal ablation technique for the treatment of uterine fibroids, which alleviates symptoms while minimizing damage to surrounding tissues. Founded in 1999 and headquartered in Tirat Carmel, Israel, InSightec has expanded its presence globally with operations in Europe, Asia, and the Americas. The Exablate system has received various regulatory approvals, including CE marks and FDA approval, and has been recognized with multiple innovation awards for its contributions to healthcare. In addition to its medical devices, InSightec provides clinical training, business support, maintenance, and customer services to healthcare facilities using its technology.

Context Therapeutics LLC is a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focused on developing innovative therapies for hormone-responsive cancers. Founded in 2015, the company’s primary aim is to address female hormone-dependent cancers, including breast, ovarian, and endometrial cancer. Context's lead program is Apristor (Onapristone XR), an investigational drug currently in Phase 2 trials for treating progesterone receptor positive metastatic breast and ovarian cancers. The company is also advancing CTX-030916, a potential oral antiprogestin designed for uterine fibroids and endometriosis. Additionally, Context is engaged in a discovery-stage program targeting Sigma1 and has developed CTIM-76, a bispecific antibody aimed at redirecting T-cell-mediated lysis towards malignant cells expressing CLDN6. Through its focused pipeline, Context Therapeutics is committed to creating effective treatments for patients with solid tumors.

Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Skye Bioscience is a San Diego-based pharmaceutical company focused on developing innovative therapeutic solutions for prevalent diseases that lack effective treatments. The company specializes in creating proprietary molecules aimed at addressing inflammatory, fibrotic, and metabolic disorders. It is particularly engaged in the modulation of cannabinoid receptor 1 (CB1) to provide novel treatment options for conditions such as obesity and glaucoma. Among its clinical candidates, Skye Bioscience is advancing nimacimab, an antibody designed to inhibit peripheral CB1 receptors for obesity treatment, and SBI-100 Ophthalmic Emulsion, a CB1 agonist intended for glaucoma management. The company's commitment to research and development positions it to contribute significantly to the biopharmaceutical landscape, particularly in the realm of cannabinoid-based therapeutics.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company offers a comprehensive digital platform that combines artificial intelligence with human support, providing users access to coaches, nutritionists, diabetes educators, nurses, trainers, and licensed therapists. This platform features personalized content, lessons, and habit recommendations, along with video sessions and messaging to facilitate communication. Vida Health's approach aims to treat the whole health of individuals by integrating mental and physical care, helping users prevent, manage, and potentially reverse chronic conditions such as diabetes and hypertension, as well as associated mental health issues like stress, depression, and anxiety. Founded in 2014, Vida Health has earned the trust of major employers and health plans in the United States for its clinically validated services.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

CMR Surgical Limited, based in Cambridge, United Kingdom, specializes in the design and manufacture of medical devices tailored for minimal access surgery. The company is recognized for its Versius surgical robotic system, which enhances laparoscopic surgical procedures by making them more accessible and affordable. Founded in 2014 and originally named Cambridge Medical Robotics, CMR Surgical aims to expand the capabilities of robotic surgery, allowing a broader range of procedures to be performed. The system provides surgeons with 3D high-definition imagery and real-time feedback, significantly improving the surgical experience and outcomes for patients.

ProMIS Neurosciences is a development-stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). It was founded in 2004 and headquartered in Toronto, Canada.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

LightForce is a company specializing in customized, 3D-printed orthodontic tools tailored to individual patient needs. The company develops a unique bracket system that takes into account the specific anatomy and tooth morphology of each patient, facilitating a more personalized orthodontic experience. LightForce's digital platform enables orthodontists to collaborate with technicians on treatment plans, leveraging modern technology and mass customization to enhance both patient outcomes and clinical efficiency. Their product range includes polycrystalline alumina brackets, bonding jigs, turbotrays, and buccal tubes, all designed to improve the overall orthodontic treatment process.

Relievant Medsystems, Inc. is a medical device company focused on developing minimally invasive treatments for chronic axial low back pain. The company has created the Intracept procedure, which specifically targets the basivertebral nerve to alleviate chronic vertebrogenic low back pain. By delivering targeted energy into the spine, the Intracept System effectively blocks the transmission of pain signals, providing patients with a low-risk therapeutic option. Founded in 2004, Relievant is headquartered in Minneapolis, Minnesota, with additional operations in Sunnyvale, California.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

Ceribell, Inc. is a medical technology company that designs and manufactures devices for electroencephalography (EEG) data acquisition and interpretation, aimed at improving the diagnosis and management of neurological conditions. Its flagship product, the Ceribell EEG System, includes a flexible EEG Headband that accommodates various hair types and head sizes, alongside a portable EEG Recorder that ensures clinical-quality data and on-device display. The system is designed to be set up by any healthcare provider within six minutes, making EEG testing more accessible and efficient. Notably, it features a unique function that converts brainwaves into sound, allowing for quicker detection of seizures without the need for specialized technicians. This innovation facilitates earlier diagnosis and targeted treatment for patients, particularly for non-convulsive seizures, thereby reducing the risk of complications and improving overall patient outcomes. Established in 2014 and based in Mountain View, California, Ceribell is committed to enhancing care in hospital ICUs, inpatient units, and emergency departments.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

Aerin Medical Inc. is a health technology company based in Sunnyvale, California, specializing in non-invasive treatment solutions for nasal breathing disorders. Established in 2011, the company has developed therapeutic devices that utilize low-power radiofrequency energy to remodel nasal soft tissues, effectively addressing the underlying causes of nasal congestion. Its primary products include the VivAer procedure for nasal airway obstruction and the RhinAer procedure for chronic rhinitis, both of which employ proprietary temperature-controlled technology. These solutions offer ENT physicians appealing alternatives to invasive surgery, allowing them to treat patients under local anesthesia with minimal to no downtime. Aerin Medical aims to meet the unmet needs of individuals suffering from chronic nasal airway conditions through its innovative and office-friendly product offerings.

Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

Elligo Health Research, Inc. is a healthcare organization focused on enhancing clinical research through innovative infrastructure and technology. Founded in 2016 and headquartered in Austin, Texas, the company facilitates the integration of clinical research into healthcare clinics, enabling faster development of pharmaceutical, biotechnology, and medical device products. By utilizing advanced health informatics and electronic health records, Elligo helps identify suitable patients for clinical trials and offers physicians the necessary support to conduct trials efficiently without the need for significant infrastructure investments. This approach not only accelerates patient enrollment and trial completion for sponsors but also allows patients to participate in clinical research within their own healthcare settings, minimizing logistical challenges and contributing to advancements in medical care. Additionally, Elligo empowers physicians with knowledge of emerging therapies, ultimately enhancing patient care and engagement in the research process.

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

Strateos is a company that specializes in automating laboratory processes in chemistry, biology, and tissue analysis through its advanced robotic cloud laboratory platform. By integrating cutting-edge robotics with sophisticated software for imaging and analytics, Strateos provides pharmaceutical partners with the tools to accelerate drug discovery and development. The company emerged from a merger between Transcriptic, which pioneered on-demand robotic lab services, and 3Scan, known for its automation and machine learning capabilities in tissue analysis. Strateos aims to streamline the drug discovery process by offering a comprehensive suite of technologies that transform life science methods into data-driven solutions. This approach not only enhances productivity and efficiency but also redefines the traditional research model, making it more accessible and effective for scientists. Through its innovative platform, Strateos positions itself as a valuable partner in the life sciences sector, focusing on delivering significant time and cost savings in the drug development process.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in the development and manufacture of reagents for marker multiplexing detection and analysis in the life sciences and biomedical fields. Founded in 2015, Ultivue focuses on tissue imaging and diagnostics, offering innovative technologies such as DNA-PAINT and DNA-Exchange. These technologies enable researchers to capture high-resolution microscopic images, facilitating a deeper understanding of biological processes and medical diagnostics. Ultivue's products are designed for use in fluorescent microscopy-based research, with the potential for significant applications in clinical diagnostics. The company's multiplex biomarker assays aid in tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine and enhance research discoveries related to complex tumor microenvironments.

RefleXion Medical Inc. is a medical equipment company specializing in the development of biologically-guided radiotherapy systems for cancer treatment. Its flagship innovation, the RefleXion X1 machine, is designed to deliver advanced radiation therapies such as stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). The company's biologically-guided radiotherapy (BgRT) technology utilizes positron-emission tomography (PET) imaging data to allow tumors to continuously signal their location during treatment, enabling the possibility of treating multiple tumors in a single session, especially in cases of metastasized cancers. This real-time adaptation to the biological characteristics of tumors represents a significant advancement in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic partnerships with Telix Pharmaceuticals Limited and HealthMyne Inc. to further its mission in cancer treatment innovation.

Mainstay Medical is a global medical device company based in Dublin, Ireland, with operations in the United States and Australia. The company focuses on developing innovative therapies for individuals suffering from chronic low back pain, a condition that affects a significant portion of the population. Mainstay Medical has created a FDA-approved restorative treatment aimed at addressing mechanical chronic low back pain. This treatment is designed to help restore muscle control and enhance functionality in the lumbar spine, ultimately improving the quality of life for patients. By collaborating with scientists and clinical experts, Mainstay Medical strives to provide effective solutions for those in need of relief from debilitating pain.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing innovative therapies that leverage the biology of DNA repair for cancer treatment and synthetic lethality in autoimmune diseases. The company utilizes its expertise in DNA damage response biology to create a pipeline of small molecule therapeutics aimed at selectively targeting vulnerabilities in cancer cells and inducing their self-destruction through DNA damage overload. Cyteir's lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, which is crucial for repairing double-strand DNA breaks. The company is dedicated to addressing a variety of hematological malignancies, solid tumors, and chronic autoimmune disorders through its integrated drug development platform. Founded in 2012, Cyteir is committed to advancing next-generation therapies that can improve patient outcomes in challenging disease states.

Syapse, Inc. is a company that develops a precision medicine software platform aimed at improving cancer care through the integration and analysis of diverse clinical, molecular, treatment, and outcomes data. By leveraging real-world evidence, Syapse enables healthcare organizations to collaborate effectively, providing comprehensive patient insights that inform clinical decisions. Its primary offering, the Syapse Learning Health Network, serves as a global data-sharing network that supports oncologists and life sciences collaborators with actionable insights derived from real-world data. Founded in 2008 and headquartered in San Francisco, California, with an additional office in Radnor, Pennsylvania, Syapse works to enhance precision medicine programs and drive impactful outcomes for cancer patients. The company has also established a strategic partnership with Pfizer to further its mission in the field of precision oncology.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.

IsoPlexis is a life science technology company based in Branford, Connecticut, founded in 2013. It focuses on developing a single-cell detection system that identifies patient immune responses at the single-cell level. This innovative platform enables the assessment of therapeutic safety and efficacy, as well as the monitoring of disease progression. IsoPlexis specializes in cell-based proteomic systems and biomarkers, providing insights into functional protein biology and cellular signaling networks with high resolution. By offering these capabilities, the company aids in predicting patient responses to novel immunotherapies and cellular therapies, ultimately enhancing therapeutic development and informing clinical decisions.

Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

MedAvail Holdings, Inc. is a technology-enabled pharmacy company based in Mississauga, Canada. It integrates automated pharmacy services into clinics and other healthcare points through its proprietary technology. The company offers comprehensive services via its robotic dispensing platform, the MedAvail MedCenter, and includes home delivery operations. MedAvail primarily operates SpotRx, a telehealth-enabled retail pharmacy that provides remote pharmacist consultations through an on-site dispensing kiosk, catering mainly to Medicare patients in the United States. Additionally, the Pharmacy Technology segment focuses on developing and commercializing the MedCenter for direct sale or lease to third-party customers.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Rapid Micro Biosystems is a life sciences technology company that specializes in products designed to detect microbial contamination in the manufacturing processes of pharmaceutical, biotechnology, and personal care products. Its flagship offering, the Growth Direct System, automates and modernizes traditional microbial quality control testing, providing a non-destructive method for microbial enumeration. The company, originally established as Genomic Profiling Systems in 2006, rebranded in 2007 and is headquartered in Lowell, Massachusetts, with an additional office in Germany. In addition to its automated systems, Rapid Micro Biosystems offers a range of services, including on-site installation, regulatory compliance assistance, system certification training, and technical support, serving clients across the Americas and Europe. Their solutions are utilized in various applications such as environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and release of critical healthcare products.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Vida Health, Inc. is a virtual care company based in San Francisco, California, focused on addressing chronic physical and behavioral health conditions. The company offers a comprehensive digital platform that combines artificial intelligence with human support, providing users access to coaches, nutritionists, diabetes educators, nurses, trainers, and licensed therapists. This platform features personalized content, lessons, and habit recommendations, along with video sessions and messaging to facilitate communication. Vida Health's approach aims to treat the whole health of individuals by integrating mental and physical care, helping users prevent, manage, and potentially reverse chronic conditions such as diabetes and hypertension, as well as associated mental health issues like stress, depression, and anxiety. Founded in 2014, Vida Health has earned the trust of major employers and health plans in the United States for its clinically validated services.

Mavrik Dental Systems Ltd. specializes in the development and commercialization of biocompatible products for the professional dental market. Founded in 2012 and headquartered in Costa Mesa, California, with an additional office in Raanana, Israel, the company has created an innovative, fully automated treatment delivery platform aimed at transforming in-office dental therapies. This platform enables dentists to perform effective teeth whitening procedures with minimal discomfort, marking a significant advancement in a field that has seen little innovation over the years. Mavrik's offerings include products such as thera smile for teeth whitening, thera natural E for gum disease treatment, and denti sense for post-whitening sensitivity. The company's technology allows dental hygienists to conduct treatments efficiently, enhancing practice revenue and patient satisfaction while providing superior treatment results. Mavrik Dental Systems is committed to advancing dental care through its cutting-edge solutions, ultimately aiming to elevate the standards of patient experiences in dental practices.

Imperative Care, Inc. is dedicated to enhancing the speed and effectiveness of acute stroke treatment through innovative medical technologies. Founded in 2015 and based in Campbell, California, the company has developed a range of solutions aimed at addressing critical needs in stroke care. Among its offerings is the Large Distal Platform, a large diameter catheter designed to reach treatment sites for both ischemic and hemorrhagic strokes. Complementing this is the ZOOM Aspiration System, a comprehensive solution that works in conjunction with the Large Distal Platform and includes various trackable reperfusion catheters for effective clot removal. By advancing stroke treatment technologies, Imperative Care aims to improve patient outcomes and optimize recovery processes for those affected by strokes.

Venclose, Inc. is a medical technology company founded in 2014 and based in San Jose, California. The company specializes in developing endovenous radiofrequency ablation therapy systems aimed at treating chronic venous insufficiency. Venclose's solutions focus on improving both physician and patient experiences by offering a minimally invasive method to close damaged veins and restore healthy blood flow. Their technology features enhanced ease of navigation and positioning, provides real-time data during procedures to aid in treatment decisions, and includes a straightforward catheter plug-in, enabling doctors to effectively treat venous reflux.

Jinxin Fertility Group Limited is a prominent provider of assisted reproductive services (ARS) with operations in China and the United States. Established in 2003 and headquartered in Chengdu, China, the company offers various treatment options, including artificial insemination with either the patient's or donor's sperm and in vitro fertilization (IVF) techniques, such as conventional IVF and intracytoplasmic sperm injection (ICSI). In addition to reproductive services, Jinxin Fertility provides complementary offerings like nutrition guidance, Chinese medicine treatment, and psychological counseling to enhance patient support. The company operates several subsidiaries, including Chengdu Xinan and Shenzhen Zhongshan, as well as HRC in the United States, thereby expanding its network and service capabilities. Jinxin Fertility's commitment to high-quality care and innovative reproductive solutions has positioned it as a leader in the field.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. With ancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services.

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative molecular pharmaceuticals and antibody drugs that target various cancer systems. GenFleet's work involves developing signal transduction regulators, tumor microenvironment modulators, and transcription factors, among other therapeutic agents. The company's mission is to provide effective medical solutions that can reactivate tumor-specific immune responses and enhance the body's own immune system in combating cancer. With a commitment to advancing cancer therapies, GenFleet serves both domestic and international markets.

Akeso Biopharma, based in Zhongshan, China, operates as a contract research organization (CRO) specializing in the discovery and development of antibody and protein drugs. Founded in 2012, the company provides comprehensive CRO services to both domestic and international pharmaceutical clients, focusing on areas such as protein expression, antibody generation, assay development, and humanization. Akeso has developed an extensive biopharmaceutical research and development platform, with a robust product pipeline that includes over 30 drugs targeting cancers, autoimmune diseases, inflammation, and cardiovascular conditions. Among these, 17 drugs have progressed to clinical stages, including two first-in-class bi-specific antibody drugs. The company collaborates with various pharmaceutical firms to innovate and develop new drug candidates, establishing itself as a leader in the industry through its advanced facilities and expertise.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Quantum Surgical is a company focused on enhancing the treatment of liver cancer through minimally invasive procedures. They develop surgical robotics that provide intelligent tools for advanced percutaneous ablation therapy, which is designed to improve patient outcomes and safety in interventional oncology. By democratizing access to these innovative treatment options, Quantum Surgical aims to enable healthcare providers to more effectively cure patients and enhance their quality of life.

GRAIL, Inc. is a healthcare company dedicated to advancing technologies for early cancer detection. Founded in 2015 and headquartered in Menlo Park, California, GRAIL has developed Galleri, a screening test aimed at asymptomatic individuals over 50 years old, and DAC, a diagnostic aid designed to expedite the resolution of cancer diagnoses in patients with clinical suspicions. The company also focuses on creating minimal residual disease tests and other post-diagnostic solutions. GRAIL's innovative approach includes a pan-cancer screening test that utilizes high-intensity sequencing to analyze circulating nucleic acids in blood, enabling the potential to detect various types of cancer at early stages.

Innovent Biologics, Inc. is a prominent biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacturing, and commercialization of monoclonal antibodies. The company focuses on therapeutic areas such as oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody approved for treating various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's pipeline includes several important candidates, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma, and IBI-303, an adalimumab biosimilar for autoimmune diseases. The company is also developing innovative therapies for conditions like hypercholesterolemia and various cancers. With a robust portfolio of commercialized products and ongoing strategic collaborations with major pharmaceutical companies, Innovent aims to expand its impact in the global biopharmaceutical landscape. Founded in 2011, Innovent is recognized as one of China's leading biotechnology firms.

Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, Massachusetts, focused on developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Founded in 2013, the company is advancing its lead product, ALZ-801, an orally administered inhibitor of beta amyloid misfolding, which is currently undergoing Phase III clinical trials. In addition to ALZ-801, Alzheon is developing ALZ-1903, a preclinical candidate that also targets beta amyloid misfolding. The company aims to address cognitive and functional decline associated with neurodegeneration, leveraging a drug discovery platform that specializes in small molecule therapies to inhibit amyloid neurotoxicity and improve patient outcomes based on individual genetic and biological profiles.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Wacai is a Chinese mobile app developer specializing in personal finance management through its widely-used mobile application. Since its launch in 2009, the app has provided users with bookkeeping services and expanded its functionality to include mutual fund trading in 2013. In 2014, Wacai introduced a credit card manager feature, which has become increasingly popular among users in China. The app aims to help individuals manage their finances effectively by offering tools for personal bookkeeping, credit management, and an online community for financial assistance. With a user base exceeding 40 million, Wacai continues to enhance its platform to meet the evolving needs of its clientele.

Aerpio Pharmaceuticals, a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, is dedicated to developing innovative compounds for treating ocular diseases and diabetic complications. Its lead product candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is working on a bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema through intravitreal injection. The company has partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 as a spin-out from Akebia Therapeutics, Aerpio adopts an outsourced approach to pharmaceutical development, leveraging the expertise of its management team.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Sorrento Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative therapies for cancer, autoimmune diseases, inflammatory conditions, and neurodegenerative disorders. The company leverages its proprietary G-MAB antibody library to create a diverse range of treatments, including chimeric antigen receptor T-cell therapies, bispecific antibodies, and antibody-drug conjugates. Key products in development include anti-CD38 CAR-T therapy for multiple myeloma and a non-opioid neurotoxin, resiniferatoxin, aimed at treating severe pain in late-stage cancer and osteoarthritis. Sorrento also explores drug delivery technologies such as Sofusa, which targets the lymphatic system, and ZTlido, a lidocaine delivery system for postherpetic neuralgia. Additionally, the company is involved in various collaborations to enhance its research and development efforts, including projects focused on COVID-19 therapeutics. With a commitment to addressing significant unmet medical needs, Sorrento Therapeutics aims to advance its diverse pipeline through both innovative drug development and strategic partnerships.

LinkDoc Technology Limited, founded in 2014 and headquartered in Beijing, China, specializes in medical data solutions and oncology-focused big data platforms. The company provides structured clinical data to oncology hospitals, aiding them in addressing various scientific and clinical challenges. Additionally, LinkDoc is committed to ensuring patient privacy and data security, adhering to standards set by the US HIPAA Act. The company focuses on delivering continuous care for patients with critical diseases and offers data-driven solutions that support life sciences companies and healthcare professionals in enhancing clinical research and facilitating real-world application of medical advancements.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Tunitas Therapeutics, Inc. is a biopharmaceutical company based in San Francisco, California, focused on developing innovative protein therapeutics for individuals suffering from allergies. Founded in 2007, the company has created Epsi-gam, a genetically engineered bifunctional human fusion protein that combines elements of human IgE and IgG1, alongside allergen vaccines. Tunitas aims to provide targeted treatment options that can significantly alter the disease course for allergy sufferers, enabling them to receive therapies in their allergist’s office. The company's approach involves generating fusion proteins that inhibit key pathways in allergic cells, addressing the underlying mechanisms of IgE-mediated diseases such as asthma and severe food allergies.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

ShockWave Medical, Inc. is a medical device company based in Santa Clara, California, focused on developing and commercializing intravascular lithotripsy technology to treat calcified plaque associated with peripheral vascular, coronary vascular, and heart valve diseases. The company offers a range of catheters, including M5 for above-the-knee peripheral artery disease, C2 for coronary artery disease, and S4 for below-the-knee peripheral artery disease. Its Lithoplasty™ technology utilizes sonic pressure waves to facilitate the treatment of rigid vascular and valvular lesions, allowing for improved angioplasty outcomes and reduced reliance on stents. This innovative approach enhances vessel preparation before procedures such as drug eluting balloon placement and trans-catheter aortic valve replacement. ShockWave Medical serves a diverse clientele, including interventional cardiologists, vascular surgeons, and interventional radiologists, through a network of sales representatives, managers, and distributors across the United States and Europe. Incorporated in 2009, the company is committed to transforming cardiovascular care and improving patient outcomes.

Alzheon, Inc. is a clinical-stage biopharmaceutical company based in Framingham, Massachusetts, focused on developing innovative treatments for Alzheimer’s disease and other neurodegenerative disorders. Founded in 2013, the company is advancing its lead product, ALZ-801, an orally administered inhibitor of beta amyloid misfolding, which is currently undergoing Phase III clinical trials. In addition to ALZ-801, Alzheon is developing ALZ-1903, a preclinical candidate that also targets beta amyloid misfolding. The company aims to address cognitive and functional decline associated with neurodegeneration, leveraging a drug discovery platform that specializes in small molecule therapies to inhibit amyloid neurotoxicity and improve patient outcomes based on individual genetic and biological profiles.

Hua Medicine is a clinical-stage drug development company based in Pudong, China, specializing in innovative therapies for diabetes and central nervous system (CNS) disorders. Founded in 2009 by experienced professionals in the pharmaceutical industry, the company is advancing its lead product, Dorzagliatin, an oral medication for Type 2 diabetes, which has reached the NDA enabling stage and is currently undergoing two Phase 3 trials in drug-naive and metformin-treated patients in China. Additionally, Hua Medicine is exploring mGLUR5, a novel drug candidate aimed at treating levodopa-induced dyskinesia in Parkinson's disease. The company has secured funding from prominent international venture capital firms and has in-licensed global rights to its diabetes drug, positioning itself as a key player in the treatment landscape for these chronic conditions.

Sagimet Biosciences is a clinical-stage biopharmaceutical company based in San Mateo, California, that specializes in developing novel therapeutics for oncology and infectious diseases. The company focuses on targeting dysfunctional metabolic pathways, particularly through its expertise in fatty acid synthase (FASN) biology. Its lead drug candidate, denifanstat, is a selective FASN inhibitor designed for the treatment of nonalcoholic steatohepatitis (NASH) and is administered as an oral, once-daily pill. Additionally, Sagimet is working on antiviral therapeutics aimed at addressing respiratory syncytial virus, cytomegalovirus, and other human pathogens. Originally known as 3-V Biosciences, Inc., the company rebranded to Sagimet Biosciences in August 2019 and has been active since its incorporation in 2006.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of anticalin-based drugs. Anticalins are engineered proteins derived from naturally occurring lipocalins, which have the ability to bind and transport a variety of molecules. The company's clinical pipeline includes PRS-060, a drug candidate in Phase I trials for asthma and inflammatory diseases, and PRS-343, a bispecific protein also in Phase I trials for oncology. Additionally, Pieris is advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, which targets hepcidin for treating iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials. Pieris has established strategic partnerships with several organizations, including Les Laboratoires Servier and AstraZeneca, and engages in research collaborations with academic institutions such as the University of Pittsburgh. The company was incorporated in 2000 and aims to address high unmet medical needs across various therapeutic areas, including cancer and severe asthma.

Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

ImmunGene Inc. is a biotechnology company based in Thousand Oaks, California, dedicated to the discovery and development of monoclonal antibody-based therapeutics aimed at treating cancer, autoimmune disorders, and other diseases. Its product pipeline features several candidates, including IGN002 for non-Hodgkin lymphoma and B cell-driven malignancies, IGN001 for breast cancer and other tumors, IGN003 targeting multiple myeloma, IGN004 for multiple solid tumors and melanomas, IGN005 for acute myeloid leukemia and related conditions, and IGN006 for additional solid tumors. The company also engages in a joint venture, Valor Biotherapeutics, LLC, with Caliber Biotherapeutics, LLC, focusing on the clinical development and commercialization of monoclonal antibody-interferon fusion protein therapeutics for cancer treatment. ImmunGene is supported by federal grants, including NIH-SBIR, and private investments from biotechnology executives, which aids in its ongoing research and development efforts.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.